Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology

Duo Will Expand Body’s Intake Capacity For Injected Medicines

Executive Summary

ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.

You may also be interested in...



ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi

License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.

GSK Promotes Ease Of Switching HIV Patients To Monthly Injection, Even During A Pandemic

Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection. 

Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic

Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel